CurveBeam AI Advances China Push and Robotic Surgery Integration for HiRise™

An announcement from Curvebeam AI Ltd. ( (AU:CVB) ) is now available.

CurveBeam AI Ltd., a medical imaging specialist focused on advanced orthopedic and weight-bearing 3D systems like its HiRise™ platform, is positioning itself for international growth with a particular focus on China. The company is working with regional partners such as WEGO Orthopaedics to support sales development, training, and technology transfer as it prepares for broader commercial rollout.

In the third quarter of fiscal 2026, CurveBeam AI received purchase orders for five devices, four of which were HiRise™, underscoring rising demand for its flagship system. The firm reported progress on its HiRise™ regulatory application in China, compiling supplemental data to stay on track for expected clearance in the second half of the calendar year, which would unlock Chinese sales, milestone payments, and follow-on revenues, while ongoing collaboration with a senior R&D leader in robotic surgery aims to finalize clinical data for HiRise™ compatibility and further strengthen its market positioning.

The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.

More about Curvebeam AI Ltd.

CurveBeam AI Ltd. operates in the medical imaging technology sector, developing advanced orthopedic imaging systems such as its HiRise™ device. The company focuses on weight-bearing and 3D imaging solutions for musculoskeletal and surgical applications, with a growing emphasis on international expansion, including the Chinese market through its partnership with WEGO Orthopaedics.

Average Trading Volume: 603,628

Technical Sentiment Signal: Sell

Current Market Cap: A$27.23M

Find detailed analytics on CVB stock on TipRanks’ Stock Analysis page.